SAFETY of INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension

Retina

Volumn 37, Issue 7, 2017, Pages 1352-1359

  Malclès, Ariane ^a   Dot, Corinne ^b,c   Voirin, Nicolas ^a   Vié, Anne Laure ^a   Agard, Émilie ^b,c   Bellocq, David ^a   Denis, Philippe ^a   Kodjikian, Laurent ^a  

^a CROIX ROUSSE HOSPITAL   (France)

^b HIA Desgenettes   (France)

^c French Military Health Service Academy   (France)

Author keywords

adverse effects; corticosteroid; dexamethasone implant; intraocular pressure; ocular hypertension; ozurdex; risk factors

Indexed keywords

ACETAZOLAMIDE; CORTICOSTEROID; DEXAMETHASONE; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG IMPLANT; DRUG SAFETY; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYOPIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POSTSURGICAL MACULAR EDEMA; PSEUDOPHAKIA; RETINA VEIN OCCLUSION; RETREATMENT; RETROSPECTIVE STUDY; RISK FACTOR; UVEITIS; CHEMICALLY INDUCED; DRUG EFFECTS; FRANCE; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; VISUAL ACUITY;

DEXAMETHASONE; DRUG IMPLANTS; FEMALE; FRANCE; GLUCOCORTICOIDS; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; OCULAR HYPERTENSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84992047455     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001369     Document Type: Article

References (24)

1. François J. Cortisone et tension oculaire [in French]. Ann Ocul (Paris) 1954;187:805-816.
2. McLean JM, Woods AC. Clinical and experimental observation on the use of ACTH and cortisone in ocular infammatory disease. Trans Am Ophthalmol Soc 1950;48: 293-294.
3. Johnson D, Gottanka J, Flugel C, et al. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol 1997;115:375-383.
4. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-2460.
5. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-1914.
6. Bellocq D, Korobelnik JF, Burillon C et al. Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODiC study. Br J Ophthalmol 2015;99:979-983.
7. Lowder C, Belfort R Jr, Lightman S, et al. Ozurdex HURON Study Group: dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129:545-553.
8. Dot C, El Chehab H, Russo A, Agard E. Ocular hypertension after intravitreal steroid injections: clinical update as of 201 [in French]. J Fr Ophtalmol 2015;38:656-664.
9. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol 1963;70:500-507.
10. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300.
11. Matonti F, Meyer F, Guigou S, et al. Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol 2013;91:e584-e586.
12. Caillaux V, Valtot F, Souied EH, Mimoun G. Intraocular pressure after intravitreal injection of dexamethasone implant for macular edema resulting from retinal vein occlusion. Eur J Ophtalmol 2015;25:454-458.
13. Capone A Jr, Singer MA, Dodwell DG et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 2014;34:342-351.
14. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-743.
15. Campochiaro PA, Braown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-2132.
16. Reid GA, Sahota DS, Sarhan M. Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds. Retina 2015;35:1647-1655.
17. Vié AL, Kodjikian L, Malclès A, et al. Tolerance of intravitreal dexamethasone implants in patients 2016 Jul 26. [Epub ahead of print].
18. Kiddee W, Trope GE, Sheng L, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol 2013;58:291-310.
19. Shukla D, Vidhya N, Prasad NM, et al. Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. Am J Ophthalmol 2007;144:453-454.
20. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598.
21. Hayreh SS, Zimmerman MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with centre and hemicentral retinal vein occlusion. Ophtalmology 2004;111:133-141.
22. Herbert HM, Viswanathan A, Jackson H, Lightman SL. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma 2004;13:96-99.
23. Bakri SJ, Omar AF, Iezzi R, Kapoor KG. Evaluation of multiple dexamethasone intravitreal implants in patients with macular edema associated with retinal vein occlusion. Retina 2016; 36:552-557.
24. Maturi RK, Pollack A, Uy HS, et al; Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina 2016.